Document is current

Any future updates will be listed below

DoE-Optimized Development of a PEGylated Liposomal Dry Powder Inhaler of Osimertinib Mesylate for Targeted Pulmonary Treatment of Non-Small Cell Lung Cancer

Crossref DOI link: https://doi.org/10.1007/s12247-026-10626-7

Published Online: 2026-04-01

Published Print: 2026-08

Update policy: https://doi.org/10.1007/springer_crossmark_policy

About CrossMark